Provided by Tiger Fintech (Singapore) Pte. Ltd.

HUA MEDICINE-B

4.370
-0.030-0.68%
Volume:6.77M
Turnover:29.54M
Market Cap:4.61B
PE:-15.68
High:4.460
Open:4.440
Low:4.300
Close:4.400
52wk High:4.700
52wk Low:1.100
Shares:1.06B
HK Float Shares:1.06B
Volume Ratio:0.30
T/O Rate:0.64%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.279
ROE:209.75%
ROA:-9.41%
PB:3.98
PE(LYR):-15.68
PS:11.38

Loading ...

Hong Kong Stock Movement | HUA MEDICINE-B (02552) Surges Over 14% as Commercial Transformation Shows Significant Results, Huatangning Sales Double in First Half

Stock News
·
Sep 04

Stock Track | HUA MEDICINE-B Soars 5.88% Following Impressive Interim Results and First-Time Profitability

Stock Track
·
Sep 02

Stock Track | HUA MEDICINE-B Soars 5.88% on First-Half Profitability and Successful Commercialization

Stock Track
·
Sep 02

Hong Kong Stock Movement | HUA MEDICINE-B (02552) Surges Nearly 6% Again as Company Achieves First-Half Profitability with Remarkable Autonomous Commercialization Results

Stock News
·
Sep 02

Stock Track | HUA MEDICINE-B Soars 5.02% Following Strong H1 2025 Results and Promising Outlook

Stock Track
·
Aug 29

HUA MEDICINE-B (02552) Interim Report Review: First-Time Profitability During Reporting Period, Commercialization Transformation Entering Harvest Phase

Stock News
·
Aug 29

BRIEF-Hua Medicine Posts H1 Revenue Of RMB 217.4 Million

Reuters
·
Aug 28

Press Release: Hua Medicine Announces 2025 Interim Results

Dow Jones
·
Aug 28

HUA MEDICINE-B (02552) Achieves First-Time Profitability in First Half, Accelerates Overseas Expansion

Stock News
·
Aug 28

Hua Medicine H1 Revenue RMB 64.2 Million

THOMSON REUTERS
·
Aug 28

Corrected-Hua Medicine H1 Revenue RMB 217.4 Million (Corrects Amount)

THOMSON REUTERS
·
Aug 28

Hua Medicine Forecasts Significant Profit Increase for 2025 Following Termination of Bayer Agreement and Successful Commercialization of HuaTangNing

Reuters
·
Jul 28

Hua Medicine - Expects RMB1,184.1 Mln Profit for Hy

THOMSON REUTERS
·
Jul 28

Hua Medicine Announces Resignation of Non-Executive Director Dr. Fangxin Li Effective June 25, 2025

Reuters
·
Jun 25